Investor2014 Wednesday, 10/21/20 07:35:25 AM Re: McMagyar post# 277543 Post # of 286190 Yes the trials if taking place in Australia will be cheaper, but the pivotal P3 trials will most likely be conducted out of the U.S. and hence discussions and guidance from the FDA. Already the AD P2a/3 trial has expanded into Europe and Canada. Although Missling claimed in the quarterly CC that trial cost would not go up as result, I think that is not strictly true. Only technical true, but not with cash tax credit of 43% like in Australia. Still unlikely to eat too much into the $250M shelf especially if SP ascends on the readouts this year and stabilises higher. Some additional funding will be required from somewhere, but I suspect Missling won’t take them from any partners until pivotal results are in and valuation is up.